The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
- Author(s)
- Dina Baier, Beatrix Schönhacker-Alte, Mate Rusz, Christine Pirker, Thomas Mohr, Theresa Mendrina, Dominik Kirchhofer, Samuel M. Meier-Menches, Katharina Hohenwallner, Martin Schaier, Evelyn Rampler, Gunda Koellensperger, Petra Heffeter, Bernhard Keppler, Walter Berger
- Organisation(s)
- Department of Inorganic Chemistry, Department of Analytical Chemistry
- External organisation(s)
- Medizinische Universität Wien, Research Cluster Translational Cancer Therapy Research
- Journal
- Pharmaceutics
- Volume
- 14
- No. of pages
- 27
- DOI
- https://doi.org/10.3390/pharmaceutics14020238
- Publication date
- 01-2022
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 301209 Pharmacy, 301206 Pharmacology
- Keywords
- ASJC Scopus subject areas
- Pharmaceutical Science
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Portal url
- https://ucrisportal.univie.ac.at/en/publications/f8607c70-cdf8-4306-98b8-56606f79cff0